Sustained Therapies

Company Overview

Snapshot

Founded in April 2022, Sustained Therapies operates with 1–10 employees. The company has secured funding across one round from one investor, AgChimedes Group, to develop antibiotic alternatives for bacterial and viral diseases.

Business overview

Sustained Therapies is dedicated to reducing reliance on antibiotics by developing sustainable solutions for bacterial and viral diseases in global livestock and crop production. The company's core technology leverages highly specific bacteriophages for antibacterial applications and gene editing/silencing (RNAi) for antiviral solutions. These biopesticide-classified solutions are applicable across poultry, aquaculture, and plants, serving the agriculture and food technologies sector.

Company Intelligence Q&A

What is Sustained Therapies' primary focus?

Sustained Therapies focuses on developing antibiotic alternatives to combat bacterial and viral diseases in global livestock production and crop plants, aiming to reduce humanity's reliance on traditional antibiotics.

What technologies does Sustained Therapies utilize?

Sustained Therapies utilizes highly specific bacteriophages for antibacterial solutions and gene editing and silencing (RNAi) for antiviral solutions, which are classified as biopesticides.

Which industries does Sustained Therapies serve?

Sustained Therapies serves the agriculture and food technologies sector, with applications in poultry, aquaculture, and plants.

When was Sustained Therapies founded?

Sustained Therapies was founded in April 2022.

Who is the CEO of Sustained Therapies?

Marina Lysenko and Dr. Inbar serve as CEOs at Sustained Therapies.